

21st October, 2022

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub: Compliance as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed the Related Party Transactions for the half year ended on 30-Sep-22.

Kindly take note of the above.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI COMPANY SECRETARY

Encl: A/a

Related Party Transaction details for the half year ended September 30, 2022 Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party (listed entity In case any financial indebtedness is In case monies are due to /subsidiary) entering into the incurred to make or give loans, intereither party as a result of transaction corporate deposits, advances or Details of the counterparty the transaction Details of the loans, inter-corporate deposits, advances or investments Value of the investments Value of related party transaction Relationship of the counterparty Nature of Details of Purpose for Notes Nature (loan/ during the Type of related Details of other related party approved by Remarks on approval with the listed entity or its indebted advance/ interwhich the fund other reporting party transaction No. transaction the audit by audit committee subsidiary will be utilised ness (loan/ corporate deposit period committee (Rs. in issuance of investment) by the ultima balance balance Secured/ (Rs. in Name PAN Name PAN debt/ anv Cost Tenure **Fenure** recipient of (Rs. in (Rs. in Rate (%) nsecured Crores) funds (endother etc.) Crores) Crores) sage) Torrent Pharmaceuticals Limited Orrent Power Limited Subsidiary of Parent Company Any other transaction Transfer of gratuity/leave 0.29 Total approval of Rs. 2 liability to / (from) cores for Transfer of Gratuity & leave balance Subsidiary of Parent Company Torrent Pharmaceuticals Limited Orrent Gas Private Limited Any other transaction Transfer of gratuity/leave of employees transferred 0.23 liability to / (from) to/ or from Torrent Power Limited, Torren Torrent Pharmaceuticals Limited TCL Cables Private Limited Step down subsidiary of Parent Gas Private Limited and 0.08 Any other transaction Transfer of gratuity/leave their subsidiaries iability to / (from) Company Forrent Pharma Inc.(TPI), USA Wholly owned subsidiary 410.51 Torrent Pharmaceuticals Limited Sale of goods or 807.17 808.40 Torrent Pharmaceuticals Limited Forrent Do Brazil Ltda. (TDBL), Brazil 257.80 Wholly owned subsidiary Sale of goods or 192.43 201.02 ervices Torrent Pharmaceuticals Limited Torrent Pharma Philippines Inc. (TPPI), Wholly owned subsidiary Sale of goods or 52.59 58.62 61.30 Philippines Wholly owned subsidiary Torrent Pharmaceuticals Limited aboratories Torrent (Malaysia) Sdn. Bhd., Sale of goods or 42.87 16.13 21.11 (LTM), Malaysia ervices Torrent Pharmaceuticals Limited ZAO Torrent Pharma (ZAO), Russia Wholly owned subsidiary Sale of goods or 53.31 38.93 54.42 ervices Torrent Pharmaceuticals Limited Heumann Pharma GmbH & Co Generica KG. Sale of goods or Step down subsidiary 95.99 (19.19)31.31 Germany services 10 Torrent Pharmaceuticals Limited Heunet Pharma GmbH, Germany 27.31 (20.35) (0.23)Step down subsidiary Sale of goods or services 11 Torrent Pharmaceuticals Limited Laboratorios Torrent S.A. de C.V. (LTSA), Wholly owned subsidiary Sale of goods or 9.64 4.27 3.40 Mexico ervices Torrent Pharmaceuticals Limited orrent Pharma (UK) Ltd (TPUK), UK Wholly owned subsidiary Sale of goods or 26.02 39.15 32.28 Torrent Pharmaceuticals Limited Forrent Pharma (Thailand) Co.Ltd., Thailand Wholly owned subsidiary Sale of goods or 0.13 0.71 0.06 ervices Torrent Pharmaceuticals Limited Forrent Pharma GmbH (TPG), Germany Wholly owned subsidiary Purchase of goods or 2.64 0.18 ervices 3.25 Torrent Pharmaceuticals Limited Jinesh Shah Key management personnel of Remuneration @ entity or parent Torrent Pharmaceuticals Limited Shailesh Haribhakti 0.26 Independent Director Any other transaction Commission to non-executive directors ^ Haigreve Khaitan 0.24 Torrent Pharmaceuticals Limited Independent Director Any other transaction Commission to non-executive directors ^ Torrent Pharmaceuticals Limited 0.26 Ameera Shah Independent Director Any other transaction Commission to non-executive directors ^ 0.25 Torrent Pharmaceuticals Limited Independent Director Navantara Bali Any other transaction Commission to non-executive directors ^ Shailesh Haribhakti Torrent Pharmaceuticals Limited Independent Director 0.11 Any other transaction Sitting fees to non-executive directors ^ Torrent Pharmaceuticals Limited Haigreve Khaitan Independent Director 0.10 Any other transaction Sitting fees to non-executive directors ^ 22 Torrent Pharmaceuticals Limited Ameera Shah Independent Director 0.04 Any other transaction Sitting fees to non-executive directors ^ Independent Director Torrent Pharmaceuticals Limited Navantara Bali 0.09 Any other transaction Sitting fees to non-executive directors ^ Dr. Maurice Chagnaud Torrent Pharmaceuticals Limited Independent Director 0.07 Any other transaction Sitting fees to non-executive directors ^ 25 Torrent Pharmaceuticals Limited Manish Mahendra Choksi Independent Director 0.01 Any other transaction Sitting fees to non-executive directors ^ Relatives of KMPs 1.29 Torrent Pharmaceuticals Limited Aman Mehta Remuneration # 1.29 Torrent Pharmaceuticals Limited Aman Mehta 0.90 0.90 Key management personnel of Remuneration @ # entity or parent Forrent Pharmaceuticals Ltd Employees Group 45.00 Torrent Pharmaceuticals Limited Trust set up by the Company for Any other transaction Contribution to employee 20 Gratuity Scheme employee benefit plans benefit plans (net) Torrent Pharmaceuticals Limited Forrent Pharmaceuticals Ltd Employees Group 0.21 Advance 0.00% Repayable on Unsecured Advance 0.21 Trust set up by the Company for Gratuity Gratuity Scheme mployee benefit plans ayment to mployees Torrent Pharmaceuticals Limited Corrent Pharmaceuticals Ltd Employees Trust set up by the Company for Any other transaction Contribution to employee 9.27 0.00 0.00 uperannuation Scheme benefit plans (net) employee benefit plans 22.00 Torrent Pharmaceuticals Limited Corrent Investments Private Limited Any other transaction Rent for leasing of land 0.02 0.01 0.01 Parent Company Torrent Pharmaceuticals Limited orrent Pharma GmbH (TPG), Germany Wholly owned subsidiary Purchase of goods or 0.11 0.01 services 33 Torrent Pharmaceuticals Limited Torrent Australasia Pty Ltd. (TAPL), Australia Wholly owned subsidiary Purchase of goods or 0.09 0.13 0.04

ervices

Related Party Transaction details for the half year ended September 30, 2022 Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

| | Details of the party (listed entity /subsidiary) entering into the transaction Details of the counter | | | | party | | | Value of the | | Value of | In case monies are due to either party as a result of the transaction | | In case any financial indebtedness is | | | Details of the loans, inter-corporate deposits, advances or investments | | | | | | |
|------------|---|-----|---|-----|---|-----------------------------------|--|--|---|--|---|-------------------|---------------------------------------|--|------|---|---|----------------------|------------------------|-----------------------|--|--|
| Sr. No. | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Type of related party transaction | Details of other related party transaction | related party transaction as approved by the audit committee (Rs. in Crores) | Remarks on approval by audit committee | transaction during the reporting period (Rs. in Crores) | Opening balance (Rs. in Crores) | balance (Rs in | indebted | Details of other ndebtedne ss | Cost | Tenure | Nature (loan/ advance/ inter- corporate deposit/ investment) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage) | tes |
| 34 | Forrent Pharmaceuticals Limited | | Torrent Power Limited | | Subsidiary of Parent Company | Purchase of goods or services | | 25.00 | - | 11.32 | 1.60 | 1.91 | | | | | | | | | | |
| 35 | Torrent Pharmaceuticals Limited | | UNM Foundation (Formerly known as Tornascent Care Institute) | | Associate | Any other transaction | Contribution towards CSR activity | y 11.29 | - | 0.25 | - | - | | | | | | | | | | |
| 36 | Torrent Pharmaceuticals Limited | | Torrent Pharma Inc.(TPI), USA | | Wholly owned subsidiary | Any other transaction | Expenses reimbursement | | - | -3.56 | | | | | | | | | | | | |
| 37 | Torrent Pharmaceuticals Limited | | Torrent Australasia Pty Ltd. (TAPL), Australia | | Wholly owned subsidiary | Any other transaction | Expenses reimbursement | | - | 0.57 | 0.03 | 0.02 | | | | | | | | | | |
| 38 | Torrent Pharmaceuticals Limited | | ZAO Torrent Pharma (ZAO), Russia | | Wholly owned subsidiary | Any other transaction | Expenses reimbursement | | - | - | 4.23 | 6.67 | | | | | | | | | | |
| 39 | Torrent Pharmaceuticals Limited | | Torrent Pharma Inc.(TPI), USA | | Wholly owned subsidiary | Purchase of fixed assets | | | - | 44.92 | - | - | | | | | | | | | | |
| 40 | Γorrent Pharmaceuticals Limited | | TPL (Malta) Limited | | Wholly owned subsidiary | Any other transaction | Equity contribution | | - | - | 8.55 | 8.55 | | | | | | | | | | |
| 41 | Torrent Pharmaceuticals Limited | | Torrent Pharma Inc.(TPI), USA | + | Wholly owned subsidiary | Any other transaction | Recovery of expenses | | - | 3.44 | 6.39 | 6.41 | | | | | | | | | | |
| 42 | Torrent Pharmaceuticals Limited | | Torrent Pharma Inc.(TPI), USA | | Wholly owned subsidiary | Any other transaction | Guarantee Commission Income | | - | 5.26 | 4.71 | 4.95 | | | | | | | | | | |
| 43 | Torrent Pharmaceuticals Limited | | Torrent Pharma Philippines Inc. (TPPI), | | Wholly owned subsidiary | Any other transaction | Guarantee Commission Income | | - | 0.18 | 0.17 | 0.28 | | | | | | | | | | |
| 44 | Forrent Pharmaceuticals Limited | | Philippines Torrent Pharma Inc.(TPI), USA | | Wholly owned subsidiary | Any other transaction | Guarantees (withdrawal)/ given (net) (including exchange rate variation) | | - | - | 765.65 | 823.68 | | | | | | | | | | |
| 45 | Forrent Pharmaceuticals Limited | | Torrent Pharma Philippines Inc. (TPPI), Philippines | | Wholly owned subsidiary | Any other transaction | Guarantees (withdrawal)/ given (net) (including exchange rate variation) | | - | - | 30.32 | 32.62 | | | | | | | | | | |
| 46 | Torrent Pharmaceuticals Limited | | Torrent Power Limited | | Subsidiary of Parent Company | Any other transaction | , | | - | - | 1.33 | 1.33 | | | | | | | | | | |
| 47 | Forrent Pharmaceuticals Limited | | Torrent Power Limited | | Subsidiary of Parent Company | Any other transaction | Security deposits given | | - | | 0.66 | 0.66 | | | | | Inter-corporate deposit | 4.25% | - | Unsecured | Regulatory Regulatory Requirement requirement det | posit as per gulatory uirement. erest rate % is as ermined by gulatory hority from e to time. |
| 48 | Torrent Pharmaceuticals Limited | | Torrent Do Brazil Ltda. (TDBL), Brazil | | Wholly owned subsidiary | Investment | | | - | • | 31.11 | 31.11 | | | | | | | | | | |
| | Forrent Pharmaceuticals Limited Forrent Pharmaceuticals Limited | _ | ZAO Torrent Pharma (ZAO), Russia ZAO Torrent Pharma (ZAO), Russia | | Wholly owned subsidiary Wholly owned subsidiary | Investment Any other transaction | Provision for diminition in value | | - | - | 58.80 | 58.80 23.08 | | | | | | - | | | | |
| | Torrent Pharmaceuticals Limited | | Torrent Pharma GmbH (TPG), Germany | - | Wholly owned subsidiary | Investment | of investment | | _ | | 23.37 | 23.37 | | | | | | | | | | |
| | Forrent Pharmaceuticals Limited | | Torrent Pharma Philippines Inc. (TPPI), | | Wholly owned subsidiary | Investment | | | | | 4.75 | | | | | | | | | | | |
| | | | Philippines | _ | | | | | - | - | | | | | | | | | | | | |
| | Torrent Pharmaceuticals Limited | | Torrent Pharma Inc.(TPI), USA | | Wholly owned subsidiary | Investment | | | - | - | 4.99 | 4.99 | | | | | | | | | | |
| 54 | Forrent Pharmaceuticals Limited | | Laboratorios Torrent S.A. de C.V. (LTSA), Mexico | | Wholly owned subsidiary | Investment | | | - | - | 27.99 | 27.99 | | | | | | | | | | |
| 55 | Torrent Pharmaceuticals Limited | | Torrent Australasia Pty Ltd. (TAPL), Australia | | Wholly owned subsidiary | Investment | | | - | - | 0.30 | 0.30 | | | | | | | | | | |
| 56 | Torrent Pharmaceuticals Limited | | Torrent Pharma (UK) Ltd (TPUK), UK | + | Wholly owned subsidiary | Investment | | | - | - | 1.68 | 1.68 | | | | | | | | | | |
| 57 | Torrent Pharmaceuticals Limited | | Torrent Pharma (Thailand) Co.Ltd., Thailand | + | Wholly owned subsidiary | Investment | | | - | - | 2.10 | 2.10 | | | | | | 1 | | | | |
| 58 | Torrent Pharmaceuticals Limited | | Laboratories Torrent (Malaysia) Sdn. Bhd., | + | Wholly owned subsidiary | Investment | | | - | - | 0.77 | 0.77 | | | | | | 1 | | | | |
| 59 | Torrent Pharmaceuticals Limited | | (LTM), Malaysia UNM Foundation (Formerly known as | + | Associate | Investment | | | - | - | 0.05 | 0.05 | | | | | | | | | | |
| 60 | Torrent Pharmaceuticals Limited | | Tornascent Care Institute) Samir Mehta | | Key management personnel of | Remuneration @ | | | - | - | 20.00 | - | + | | | | | 1 | | | | |
| 61 | Torrent Pharmaceuticals Limited | | TCL Cables Private Limited | + | entity or parent Step down subsidiary of Parent | Purchase of fixed | | 4.00 | - | 0.92 | - | - | | | | | | + | | | | |
| 62 | Forrent Pharmaceuticals Limited | | Khaitan & Co | + | Company Director Partner | assets Purchase of goods or | | 2.50 | - | 0.03 | - | - | | | | | | | | | | |
| 63 | Laboratories Torrent (Malaysia) Sdn. Bhd., (LTM), Malaysia | | Epsilon Advisory Services Sdn Bhd | | Director is interested | Purchase of goods or services | | | - | 0.00 | - | - | | | | | | | | | | |
| 64 | Torrent Pharma Philippines Inc. (TPPI), Philippines | | Cabrera And Company | | Director is interested | Purchase of goods or services | | | - | 0.01 | 0.01 | 0.00 | | | | | | | | | | |
| 65 | Heumann Pharma GmbH & Co Generica KG, Germany | | Torrent Pharma Inc.(TPI), USA | | Fellow Subsidiary of Holding company | Loan | | | - | - | 303.23 | 326.21 | | | | | Loan | 4.75% | 3 years, extendable | Unsecured | Business Purpose | |
| 66 | Heumann Pharma GmbH & Co Generica KG, Germany | | Torrent Pharma Inc.(TPI), USA | + | Fellow Subsidiary of Holding company | Interest received | | | - | 7.48 | 3.55 | 3.90 | | | | | | | CATCHUAUIC | | т агрозс | |

Related Party Transaction details for the half year ended September 30, 2022

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Details of the party (listed entity In case monies are due to In case any financial indebtedness is /subsidiary) entering into the incurred to make or give loans, intereither party as a result of transaction Details of the counterparty the transaction corporate deposits, advances or Details of the loans, inter-corporate deposits, advances or investments investments Value of the Value of related party transaction Purpose for which the funds Nature of | Details of Notes Relationship of the counterparty Nature (loan/ during the Sr. No. Type of related Details of other related party approved by Remarks on approval with the listed entity or its indebted advance/ interother reporting party transaction transaction the audit by audit committee subsidiary ness (loan/ indebtedr will be utilised corporate deposit period Closing committee by the ultimate (Rs. in issuance of SS investment) balance balance Interest Secured/ (Rs. in PAN PAN debt/ any recipient of Name Name Cost Tenure **Fenure** (Rs. in (Rs. in Rate (%) ınsecured Crores) funds (endother etc.) Crores) Crores) sage) 67 Heumann Pharma GmbH & Co Forrent Pharma (UK) Ltd (TPUK), UK Fellow Subsidiary of Holding 202.09 184.26 3.09% Loan 5 years, Secured Business Generica KG, Germany ompany Purpose Heumann Pharma GmbH & Co Forrent Pharma (UK) Ltd (TPUK), UK Fellow Subsidiary of Holding 2.69 1.43 Interest received Generica KG, Germany ompany 69 Heumann Pharma GmbH & Co Forrent Pharma GmbH (TPG), Germany Holding Company 20.34 20.03 0.99% Loan Loan Working Insecured Business Generica KG, Germany Capital urpose Requiremen Short term 70 Heumann Pharma GmbH & Co Forrent Pharma GmbH (TPG), Germany Holding Company 0.02 Interest received Generica KG, Germany Heunet Pharma GmbH, Germany Heumann Pharma GmbH & Co Generica KG, Fellow Subsidiary (40.68) 253.98 200.27 1.84% Working Loan Insecured Business Capital urpose Requiremen Short term) 72 Heunet Pharma GmbH, Germany Heumann Pharma GmbH & Co Generica KG, Fellow Subsidiary Interest received 1.18 Germany Heumann Pharma GmbH & Co Forrent Pharma (UK) Ltd (TPUK), UK Fellow Subsidiary of Holding Any other transaction Expenses reimbursement 0.16 Generica KG, Germany 74 Torrent Pharma GmbH (TPG), Heumann Pharma GmbH & Co Generica KG, Wholly owned subsidiary 31.04 31.04 Investment Germany Germany Torrent Pharma GmbH (TPG), Heunet Pharma GmbH, Germany Wholly owned subsidiary 0.17 0.17 Investment

8.17

8.17

Torrent Pharma (Malta) Limited

76 TPL (Malta) Limited

Wholly owned subsidiary

Investment

[@] excluding provision for gratuity and leave encashment, insurance premium for group personal accident and group mediclaim.

[^] excluding Goods and Services Tax.

[#] Remuneration for April-2022 to July-2022. Aman Mehta is appointed as a Director w.e.f. 01st August, 2022 and remuneration of August and September 2022 has been disclosed as Remuneration to Key Management Personnel.